Coronary heart disease (CHD), a leading cause of death in dialysis and transplant patients (1) (2) (3) (4) . has been causally related to such risk factors as long--standing hypertension, hyperlipidemia (hypertriglyceridemia, hypoalphaliproproteinemia, hyperbetalipoproteinemia), vascular calcification associated with secondary hyperparathyroidism, hyperglycemia, obesity, cigarette smoking, diabetes mellitus, and lack of consistent exercise. Its incidence, however, is several times greater than in patients with comparable hypertension or hyperlipimedia but no renal disease (5) , It would clearly be important to understand the pathophysiology of CHD in renal failure, in the hope of preventing or ameliorating this serious problem.
Hypertriglyceridemia present in most non-nephrotic uremic or maintenance dialysis patient. (6-9) is usually of the Type IV lipoprotein phenotype. Levels of very-Iowdensity (VLDL) and low-density-lipoprotein (LDL) triglyceride fractions and the very-low-density-Iipoprotein cholesterol fraction (C-VLDL) are increased, with simultaneous depression of high-density-lipoprotein cholesterol (C-HDL) and its major apolipoprotein, apoprotein AI (Apo AI); while levels of apolipoprotein B (Apo B), the major apoprotein of LDL, are normal (6) (7) (8) (9) (10) (11) ,
The pathogenesis of the hypertriglyceridemia of uremia has been the subject of much debate (12), Increased hepatic triglyceride and VLDL synthesis has been implicated, as a result of either insulin antagonism or hyperinsulinism, or increased fatty acid release from adipose tissue, Impaired triglyceride and VLDL removal resulting from reduced lipoprotein lipase activity, or due to a circulating lipoprotein lipase inhibitor, have also been suggested. Other possible factors are obesity, diabetes, and a high dietary carbohydrate intake, leading to increased VLDL synthesis. Current evidence favors defective post-heparin lipolytic activity with decreased triglyceride and VLDL removal as the cause for the defect, and it would appear that it is the hepatic lipoprotein lipase that is markedly reduced (10, 13) .
Perhaps of central importance in these patients are the low levels of HDL and Apo AI. As shown by the recent Framingham data, C-HDL appears to be the most powerful single independent lipid indicator of risk for CHD; the higher the C-HDL, the lower the risk, and viceversa (14) . Recent genetic studies have shown that families in which C-HDL is increased have prolonged longevity and decreased morbidity from myocardial infarction (15) . Plasma HDL levels are low in poorly-controlled diabetes mellitus, familial hypercholesterolemia, and familial and acquired hypertriglyceridemia, as well as in men with ischemic heart disease but no other risk factors. These observations suggest that low levels of HDL are associated with an increased cardiovascular risk rate.
In renal failure and maintenance dialysis patients the low C-HDL and high C-VLDL levels may account for the high incidence of heart disease (16) -probably on the basis of pre-existing risk factors rather than because dialysis itself might accelerate atherosclerotis (17) .
After transplantation hypercholesterolemia is more common and hypertriglyceridemia less common than in the uremic and hemodialysis patient (7, 11, 12) . Increased LDL and VLDL with lipoprotein phenotypes lIa, lib, and IV have been observed. The low Apo A levels seen in the dialysis patients persist for six months after transplantation (11) but return to normal within 12 months. Apo B levels however, which are normal in uremic and dialyzed patients, are elevated in long-term transplant recipients (11) , as are LDL levels, and this may counterbalance the benefit of Apo A levels returning to normal. These levels are inversely proportional to the serum creatinine level and the prednisone dosage (12) It would appear, then, that the hyperlipidemia following transplantation is of multifactorial etiology. The hypertriglyceridemia could be due to obesity, steroid therapy, and impaired renal function (12) . Corticosteroids elevate serum lipid levels in humans with normal renal function, and increase hepatic synthesis of VLDL in experimental animals (12) . Hyperinsulinemia has also been implicated; and reduced lipoprotein lipase activity, known to occur in allograft recipients with mildly impaired renal function (12) . would result in decreased clearance of circulating triglycerides. The cause of the hyper-cholesterolemia remains unclear, but obesity, dietary cholesterol intake, and steroids may play a role. There is less hyperlipemia in patient treated with alternate day steroids (18) or following steroid withdrawal. in HLA-identical transplants (19) .
The therapeutic approach to hyperlipidemia includes early detection, and rigid control of diabetes, hypertension, smoking, obesity, and other risk factors. Since cigarette smoking is associated with reduced C-HDL and Apo AI, it should be discontinued or reduced. A diet low in carbohydrate and high in polyunsaturated fats will reduce fasting plasma triglyceride levels but not chotss-Plasma lipidis in renal failure terol or postprandial triglycerides in patients with chronic renal failure (20) . This may be achieved by lowering the proportion of carbohydrate from 50 to 35% of total daily calories and increasing the polyunsaturated to saturated fat ratio from 0.2 to 2.0 in an isocaloric diet, a change which also lowers the triglyceride production rate and the insulin response to a meal (20) . Similarly, in maintenance dialysis patients, decreasing the proportion of carbohydrate from 50 to 35% of total daily calories lowered plasma triglycerides regardless of the type of fat used, as well as decreasing postprandial insulin responses (21) .
Clofibrate in a daily dose of 1.5-2.0 gm effectively lowers the serum triglyceride levels in patients with normal renal function. In renal failure, however, it may cause muscle toxicity (22) because it persists in plasma up to seven times as long (23) , so that the dose should be reduced to a total of 1.0-1.5 gm per week to safely lower triglyceride levels (23) . A moderate but consistent exercise program should also helps elevate C-HDL and Apo AI levels, but this is difficult to achieve when exercise capacity is limited by anemia. Following transplantation, the diet should remain low in carbohydrates and high in polyunsaturated fatty acids, and weight needs to be rigidly controlled. Clofibrate (2.0 gm per day) has effectively lowered triglyceride and cholesterol levels and decreased the C-LDL to C-HDL ratio in transplant recipients with normal renal function (24) . Alternate day steroids may also be helpful (18) , but may result in a higher rate of acute rejection episodes.
Finally, one must ask whether therapeutic intervention maker any difference to the natural history of the arterial disease in these population groups. This is not yet known, and may indeed require randomized prospective trials. We do know, however, that assiduous management of hyperlipoproteinemia in nonrenal patients may help reverse atherosclerotic arterial lesions (25) . one should hope that this can also be achieved in the renal patient, by usong safe and potentially effective measures such as dietary manipulation, regular exercise, amelioration of other risk factors, and possibly clofibrate.
